Drug Type Biosimilar, Monoclonal antibody |
Synonyms Infliximab (geneticalrecombination) |
Target |
Action inhibitors |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (04 Jul 2014), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ankylosing Spondylitis | Japan | 01 Oct 2020 | |
Behcet's uveitis | Japan | 01 Apr 2020 | |
Arthritis, Psoriatic | Japan | 22 Jul 2015 | |
Erythrodermic psoriasis | Japan | 22 Jul 2015 | |
Psoriasis vulgaris | Japan | 22 Jul 2015 | |
Pustular psoriasis | Japan | 22 Jul 2015 | |
Colitis, Ulcerative | Japan | 04 Jul 2014 | |
Crohn Disease | Japan | 04 Jul 2014 | |
Rheumatoid Arthritis | Japan | 04 Jul 2014 |